Abstract: An agent of the present invention comprising poultry feet or a processed product thereof, preferably a hydrolysate of an extract of poultry feet, promotes hyaluronic acid production, thereby exhibiting excellent effects of preventing or treating a joint disorder, improving skin dryness, wrinkles or skin tension, moisturizing the skin, etc. The agent is thus useful as a medicament, a quasi-drug, a cosmetic product, a food product or an animal feed.
Abstract: Microbes expressing cholesterol oxidoreductase (COR) proteins, methods of engineering the microbes expressing COR proteins, compositions and methods of using the microbes are provided.
Abstract: The present disclosure provides a micro-organismal product and a method for treating a patient with sickle cell disease. In one aspect, the method comprises determining a concentration of one or more biological markers in serum of the patient indicative of breach of an intestinal barrier in sickle cell disease; and administering a micro-organismal product to the patient that restores intestinal permeability of the patient by, for example, upregulating tight-junctions of the patient's intestine.
Abstract: This document relates to biomarkers of gut microbiota dysbiosis. Bacteria that are increased or decreased in gut microbiota dysbiosis can be used as biomarkers to predict dysbiosis in patients with diarrhea and/or to predict susceptibility to Clostridium difficile infection (CDI). In addition, provided herein are compositions including at least three bacteria that are decreased in gut microbiota dysbiosis which can be used, for example, to restore heathy gut microbiota (e.g., by probiotic or by fecal microbiota transplant) to treat CDI.
Type:
Application
Filed:
November 9, 2020
Publication date:
May 6, 2021
Inventors:
Purna C. Kashyap, Eric J. Battaglioli, Vanessa L. Hale
Abstract: The present invention provides a novel drug or food that can produce desired effects. More specifically, the present invention provides: an intestinal microbe having D-psicose-responsive proliferation; a drug or food containing the intestinal microbe having D-psicose-responsive proliferation; a biological function-improving agent containing the intestinal microbe having D-psicose-responsive proliferation; an intestinal microbe culturing method that includes culturing the intestinal microbe in a D-psicose-containing culture medium; a screening method for a biological function-improving agent using the intestinal microbe having D-psicose-responsive proliferation; and the like.
Abstract: An object of the present invention is to provide a novel food material effective for recovering from fatigue and/or preventing fatigue accumulation. The present invention provides a composition for use in recovering from fatigue and/or preventing fatigue accumulation, comprising a Lactococcus bacterium as an active ingredient.
Type:
Application
Filed:
February 27, 2018
Publication date:
May 6, 2021
Applicant:
Kirin Holdings Kabushiki Kaisha
Inventors:
Kazunori SHIMADA, Kosuke FUKAO, Yuta KOMANO, Toshio FUJII
Abstract: The present invention is directed to methods of administering a probiotic composition including Bacillus subtilis, Bacillus licheniformis, and Pediococcus acidilactici to dogs to decrease endotoxemia and improve the digestive process, and related methods.
Type:
Application
Filed:
September 16, 2020
Publication date:
May 6, 2021
Applicant:
Microbiome Labs, LLC
Inventors:
Kiran Krishnan, Dale M. Kriz, Thomas F. Bayne
Abstract: The present invention is directed to a novel isolated bacterial strain of the Lactobacillus casei (L. casei) species. More in particular, the strain of the Lactobacillus casei species deposited under accession number LMG P-30039. The present invention further relates to the novel L. casei strain for use in the treatment and/or prevention of infections and/or immune-related diseases. Also the use of the isolated novel L. casei strain or a composition comprising said strain as an adjuvant to promote an immune response during vaccination is disclosed. Further, the use of said novel L. casei strain or a composition comprising said strain in personal hygiene industry, cleaning industry, biomass production, air purification and food industry is disclosed. In another aspect of the present invention, the use of a L. casei species that has a whole genome G/C content of at least 47.5% and expresses one or more catalase genes or a composition comprising one or more of said L.
Type:
Application
Filed:
March 23, 2018
Publication date:
May 6, 2021
Applicants:
KU Leuven Research & Development, Universiteit Antwerpen
Inventors:
Camille Allonsius, Ilke De Boeck, Stijn Wittouck, Sander Wuyts, Sarah Lebeer, Peter Hellings
Abstract: The present invention provides a composition for promoting glucolipid metabolism, and a preparation and an application thereof, and relates to the technical field of probiotics. The composition of the present invention includes probiotics and inulin; the probiotics include Bifidobacterium longum, Bifidobacterium breve, Lactobacillus gasseri, Lactobacillus rhamnosus, Lactobacillus salivarius, Lactobacillus cripatus, Lactobacillus plantarum, Lactobacillus fermentum, and Lactobacillus casei. In the composition of the present invention, the nine strains synergize with each other, which function as a regulator of glucolipid metabolism, improve sensitivity to insulin receptor in the body, and relieve insulin resistance when reconstituted with inulin. The composition has some effects on improving serum total cholesterol and triglyceride, islet ?-cell function, and type 2 diabetes mellitus.
Abstract: Molecules secreted or derived from probiotic bacteria are provided for use in compositions and methods for the treatment and/or prevention of infection by pathogenic viruses. The isolated secreted molecules can also be used in nutritional or medical food products which provide probiotics to the gastrointestinal tract of a mammal.
Abstract: In one aspect, probiotic compositions are described herein comprising surface modified microbes operable to adhere or bind to surfaces of the gastrointestinal tract. In some embodiments, for example, a composition for enhancing gastrointestinal health comprises microbes modified with one or more surface moieties, the surface moieties comprising functionality for binding the modified microbes to surfaces of the gastrointestinal tract.
Abstract: Described herein are AAV transfer cassettes and plasmids used in the production of recombinant adeno-associated viral (rAAV) vectors. The disclosed cassettes and plasmids comprise one or more transgenes having therapeutic efficacy in the amelioration, treatment and/or prevention of one or more diseases or disorders, such as Niemann-Pick Disease, type C1 (NPC1).
Abstract: Disclosed are replication-enhanced oncolytic adenoviruses. These oncolytic adenoviruses have tumor-specific replication capable of enhanced tumor oncolysis and enhanced therapeutic transgene expression. Also disclosed are methods comprising administering a replication-enhanced oncolytic adenovirus for patients suffering from a cancer.
Type:
Application
Filed:
November 6, 2020
Publication date:
May 6, 2021
Applicants:
MEMGEN, Inc., H. Lee Moffitt Cancer Center and Research Institute, Inc.
Abstract: Provided is a composition for use in medicines, food products, supplements, or beverages that can treat, prevent, or improve male infertility. The composition for treating, preventing, or improving male infertility of the present invention contains a koji mold fermentation product obtained by fermentation with a koji mold.
Abstract: The present invention provides a composition for human or animal consumption, preferably with antiviral, antibacterial, antifungal, antiprotozoal, immune boosting and/or toxin resistance activities. The composition includes a fungal extract component and optionally a fruit extract component. The invention also provides methods for producing the composition and methods of using the composition.
Abstract: The present invention relates to a pharmaceutical composition and a food composition for preventing or ameliorating degenerative neurological disease comprising Poria cocos peel extract for preventing, or treating neurodegenerative disorders. Poria cocos peel extract which is the active ingredients contained in the composition of the present invention, has a memory ameliorating activity through inhibiting of acetylcholine esterase and a neuroprotective effect and neuron protection by inhibiting the formation of beta amyloid and tau phosphorylation and promoting NGF production. Thus, the present invention may be useful as a pharmaceutical composition for preventing or treating degenerative neurological diseases, or as a health food for the above purpose.
Type:
Application
Filed:
November 13, 2020
Publication date:
May 6, 2021
Inventors:
Sang Zin CHOI, Mi Won SOHN, Hyo Sang GO, Ja Young RYU, Jin Seok JEONG, Song Hyen CHOI, Eun Jin KIM, Young Woong CHO, So Young KIM
Abstract: The invention relates to the extraction of pharmaceutically active components from plant materials, and more particularly to the preparation of a botanical drug substance (BDS) for incorporation in to a medicament. It also relates to a BDS of given purity, for use in pharmaceutical formulations. In particular it relates to BDS comprising cannabinoids obtained by extraction from cannabis.
Type:
Application
Filed:
June 18, 2020
Publication date:
May 6, 2021
Applicant:
GW Pharma Limited
Inventors:
BRIAN ANTHONY WHITTLE, Colin A. Hill, Ian R. Flockhart, David Victor Downs, Peter Gibson, Gary William Wheatley
Abstract: A composition is produced by a method of extracting a Kanna plant, wherein the method comprises the steps of harvesting and drying the plant, extracting the alkaloids comprising Mesembrine from the plant in a solvent, and filtering the solvent-Kanna plant mixture to remove the solvent and extracted alkaloids from a spent Kanna plant matter. The method further includes drying the spent Kanna plant matter, purifying and separating the extracted alkaloids from the solvent, and mixing the extracted alkaloids back into the dried spent plant matter.
Abstract: Use of a functional thylakoid extract, particularly in admixture with a physiologically acceptable carrier, in pharmaceutical application, in the treatment of inflammatory bowel disease, and method for the treatment thereof. The inflammatory bowel disease may comprise several diseases associated with inflammation of the small intestine, large intestine (colon), rectum or anus (anal sphincter), and may be particularly selected from ulcerative colitis and Crohn's disease.
Abstract: The specification relates to a composition for enhancing immunity, comprising a ginseng berry polysaccharide as an active ingredient. The composition can increase the expression of cytokines such as IL-6, IL-12, and TNF-? by using ingredients derived from natural products. In addition, the composition can exhibit excellent immunity enhancement effects because of the unique components and structure of a ginseng berry polysaccharide.
Type:
Application
Filed:
January 26, 2018
Publication date:
May 6, 2021
Inventors:
Suhwan KIM, Juewon KIM, Chan-woong PARK, Dae Bang SEO, Donghyun CHO, Kwang Soon SHIN, Dae Young LEE
Abstract: An aspect of embodiments of the invention relates to providing novel therapeutic compositions comprising herbal extracts of the plant species Sambucus nigra, Echinacea purpurea, and Centella asiatica. The compositions exhibit increased therapeutic activity for treatment of various inflammatory diseases, in particular, inflammatory diseases of mucosa or skin relative to previously identified compositions. In addition the compositions exhibit increased solubility relative to previously identified compositions. In an embodiment of the invention, the ratio of Sambucus nigra:Echinacea purpurea:Centella asiatica is 7:1:2. An embodiment of the invention provides methods for preparing an aqueous therapeutic composition comprising extracts of the aforementioned plant species, using at least two extractions.
Type:
Application
Filed:
December 20, 2020
Publication date:
May 6, 2021
Applicant:
IZUN PHARMACEUTICALS CORP.
Inventors:
Amy Debra ROSENBLUH, Gabriel Jay NUSSBAUM, Avner ROTMAN
Abstract: Disclosed are compositions comprising Rhamnus prinoides (GESHO) extract or fragments thereof and methods of using Gesho extract for the inhibition of biofilm formation.
Abstract: The invention relates to various compositions for improving exercise performance and/or recovery. The invention also relates to methods of using these compositions and kits including these compositions to improve exercise performance and/or recovery.
Abstract: Provided is a material effective for improving the activity of nerves in the brain or for preventing or ameliorating brain dysfunction. An agent for activating astrocyte glucose metabolism, brain nerve cells activating agent, a brain hypofunction suppressing agent, a brain function improving agent, or an agent for preventing or ameliorating brain dysfunction comprising, as an active ingredient, one or more selected from the group consisting of hydrophobic solvent extracts of tien-cha, rooibos, grape and black tea.
Abstract: An oral dosage form or plurality of oral dosage forms comprising as active ingredients combinations of citric acid, magnesium citrate, phytin, pyridoxine, and musa is disclosed. The oral dosage form(s) is useful for inhibiting calcium oxalate crystal growth and for treating or inhibiting growth of kidney stones. Methods of inhibiting calcium oxalate crystal growth and of treating or preventing kidney stones are also disclosed.
Type:
Application
Filed:
December 30, 2020
Publication date:
May 6, 2021
Inventors:
Gregory K. Hayer, Brendan Magrab, Henry R. Wolfe, JR.
Abstract: A topical formulation and method of using the formulation on animals including dogs is disclosed. The formulation is used to facilitate the healing of cuts, scrapes, abrasions, and other conditions often experienced by animals. A main ingredient of the formulation is sulfur in a high concentration.
Abstract: Provided herein are methods of treating autoimmune diseases comprising administering to a subject suffering therefrom an immunoproteasome inhibitor and an immunosuppressive agent.
Abstract: The present invention is directed to tetramaleimide linkers and use thereof, more specifically to the compounds represented by formula I and their use in the preparation of antibody-drug conjugates (ADCs). The ADCs obtained from the tetramaleimide linkers have high homogeneity and stability, and could be used effectively for the treatment of various diseases including tumors. The definition of the groups in formula I is the same as that in the description.
Type:
Application
Filed:
April 18, 2018
Publication date:
May 6, 2021
Inventors:
Deqiang AN, Nianhe HAN, Peng ZHU, DI ZENG, Baoxiang WANG, Huali LI, Chun YANG
Abstract: Disclosed herein are linear lipopeptides having antimicrobial and antibiofilm activity. In one aspect of the invention the linear lipopeptide comprising a lipophilic terminus, an amine terminus, and a peptide interposed between the lipophilic terminus and the amine terminus or a salt thereof. The peptide may comprise any of SEQ ID Nos: 1-17 or a derivative thereof. Products comprising the lipopeptides and methods of using the same are also disclosed.
Type:
Application
Filed:
August 6, 2018
Publication date:
May 6, 2021
Applicant:
BioVentures, LLC
Inventors:
En Huang, Sun Hee Moon, Mark Smeltzer, Daniel Meeker
Abstract: The invention features pharmaceutical compositions, methods, and kits featuring dosing gimens and oral dosage formulations for administration of echinocandin class compounds.
Abstract: Provided herein are compositions and methods for treating dry eye or an ocular disease associated with inflammation in a subject in need thereof. The therapeutic compositions comprise an adiponectin peptidomimetic compound, and a pharmaceutically acceptable carrier. Also provided are methods for alleviating one or more symptoms or clinical signs of dry eye or an ocular disease associated with inflammation in a subject in need thereof.
Abstract: The present invention relates to the use of a gonadotropin-releasing hormone (including GnRH I, a GnRH I analogue, GnRH II, or a GnRH II analogue) as adjuvant immunotherapeutic.
Abstract: The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect. The present disclosure also provides for methods for treating prostate cancer in a patient with a history of at least one cardiovascular event, wherein administration of degarelix to the subject decreases the likelihood of developing or experiencing an additional cardiovascular event compared to treatment with a gonadotrophin releasing hormone (GnRH) agonist.
Type:
Application
Filed:
May 21, 2020
Publication date:
May 6, 2021
Inventors:
Egbert A. van der Meulen, Laszlo Balazs Tanko
Abstract: Aspects of the disclosure relate to compositions comprising Luteinizing Hormone Releasing Hormone (LHRH) or an analog of LHRH conjugated to prodigiosin, and methods of treatment of cancer, for example, triple negative breast cancer, using such compositions.
Type:
Application
Filed:
October 30, 2020
Publication date:
May 6, 2021
Inventors:
Winston O. Soboyejo, John D. Obayemi, Ali A. Salifu, Vanessa O. Uzonwanne
Abstract: Aspects of the disclosure relate to compositions comprising Luteinizing Hormone Releasing Hormone (LHRH) or an analog of LHRH conjugated to paclitaxel, and methods of treatment of cancer, for example, triple negative breast cancer, using such compositions.
Type:
Application
Filed:
October 30, 2020
Publication date:
May 6, 2021
Inventors:
Winston O. Soboyejo, John D. Obayemi, Ali A. Salifu, Vanessa O. Uzonwanne
Abstract: The principles and embodiments of the present disclosure relate to methods of increasing survival of a patient having type 1 hepatorenal syndrome (HRS-1) and low mean arterial pressure (MAP). The methods may include identifying a patient having HRS-1 that has a baseline MAP of less than 65 mmHg, and administering, to the patient, an amount of terlipressin effective to treat the HRS-1 in the patient. In other aspects, the method may include administering an effective dose of terlipressin to a patient in need thereof every 6 hours by intravenous (IV) bolus injection over 2 minutes, where the dose is sufficient to yield an increase in MAP and decrease in heart rate in the patient. The patient may not have overt sepsis, septic shock, or uncontrolled infection.
Type:
Application
Filed:
October 29, 2020
Publication date:
May 6, 2021
Inventors:
Khurram Jamil, Stephen Chris Pappas, Peter Teuber
Abstract: Disclosed are ophthalmic compositions, methods for using the compositions and kits comprising the compositions for treating dry eye in a subject in need thereof. The composition comprises at least one peptide that is an inhibitor of trans-endothelial migration, an analogue, variant, derivative, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient for treating dry eye and ocular diseases of inflammation.
Abstract: The present invention relates to a synergistic pharmacological association of NAC and colistin for use in the treatment of a bacterial infection caused by one or more pathogens selected from S. maltophilia and A. baumannii strains, in particular a bacterial infection associated with a respiratory tract disease, such as a chronic respiratory tract disease comprising CF, bronchiectasis non CF and COPD.
Type:
Application
Filed:
February 26, 2018
Publication date:
May 6, 2021
Applicant:
Zambon S.P.A.
Inventors:
Lucia Pallecchi, Francesco Sergio, Gian Maria Rossolini
Abstract: Disclosed are methods of treating, inhibiting, or preventing the development of, a food allergy in a patient by administering a therapeutically effective amount of a thiol isomerase inhibitor to a patient in need thereof. Also disclosed are methods for treatment of other allergic diseases and inflammatory diseases.
Abstract: Provided herein are synthetic peptides and methods for treating cardiorespiratory diseases, particularly cardiopulmonary disorder (CPD) by use of the synthetic peptides. The present synthetic peptide has the amino acid sequence of X1EX2LRVANEVTLN (SEQ ID NO: 1), in which X1 is tyrosine (Y) or phenylalanine (F), and X2 is alanine (A) or cysteine (C). In preferred embodiments, an effective amount of the present synthetic peptide is administered to a subject suffering from CPD to ameliorate or alleviate symptoms associated therewith.
Type:
Application
Filed:
October 30, 2019
Publication date:
May 6, 2021
Applicants:
Chang Gung University, Chang Gung Memorial Hospital, Linkou
Inventors:
Ying-Ju LAI, Pao-Hsien CHU, Whei-Yang Winston KAO
Abstract: The invention relates inter alia to a protein which is a VTFT isoform of a BPIFB4 protein or a functional fragment thereof for use in the treatment or prophylaxis of a condition selected from neuronal diseases and injuries, said diseases and injuries being associated with mitochondrial dysfunction and/or protein aggregation and/or ameliorated by CXCR4 activation.
Abstract: This invention relates to a topical gel drug product preparation containing a composition comprising an isolated polypeptide having a carboxy-terminal amino acid sequence of an alpha connexin (ACT peptide), peptide stabilizers, excipients, buffering agents, and the like. A formulation and preparation steps are disclosed for the manufacturing of a stable, elegant, and pourable topical gel. The resulting formulation possesses long term stability suitable for aesthetic as well as therapeutic applications including the prevention of scaring and accelerated healing of wounds. Methods for treatment of chronic wounds, including chronic ulcers, are also provided.
Abstract: The present invention provides a novel chemokine receptor antagonistic modified peptide. The novel chemokine receptor antagonistic modified peptide can be combined with a chemotherapeutic drug for treating cancer, especially for treating drug-resistant cancer, and inhibiting tumor growth more effectively.
Abstract: Novel anti-tumor agents comprising at least one ligand of the B7h receptor, wherein the ligand of receptor B7h is loaded in a biocompatible micro- or nano-carrier and is able of binding to receptor B7h and triggering receptor B7h activity.
Type:
Application
Filed:
January 9, 2019
Publication date:
May 6, 2021
Inventors:
Umberto DIANZANI, Casimiro Luca GIGLIOTTI, Elena BOGGIO, Nausicaa CLEMENTE, Annalisa CHIOCCHETTI, Francesco TROTTA, Roberta CAVALLI, Chiara DIANZANI
Abstract: A pharmaceutical composition or method for promoting meibomian gland regeneration or for treating/preventing dry eye syndrome includes administering to a subject in need thereof a pharmaceutical composition comprising a PEDF-derived short peptide (PDSP) or a variant of the PDSP, wherein the PDSP comprises residues 93-106 of human pigmented epithelium-derived factor (PEDF).
Type:
Application
Filed:
May 4, 2019
Publication date:
May 6, 2021
Applicant:
BRIM Biotechnology, Inc.
Inventors:
Nai-Wen Fan, Tsung-Chuan Ho, Yeou-Ping Tsao, Frank Wen-Chi Lee
Abstract: A bone repair material, a preparation method of the bone repair material, and a biological composite scaffold are provided. The bone repair material includes: a base material, and a carbon nanomaterial and a polypeptide both mixed with the base material; and the carbon nanomaterial and the polypeptide are bonded by chemical bonds. The preparation method includes: bonding a carbon nanomaterial with a polypeptide by chemical bonds; and mixing the carbon nanomaterial and the polypeptide bonded by the chemical bonds with a base material, and performing a molding treatment.
Abstract: The present invention refers to soluble Neuregulin-1 isoforms representing Posttranslational Neuregulin-1 modifications as medication in cognition-related neurological disorders, in particular schizophrenia, Alzheimer's and Parkinson's diseases.
Abstract: The present invention examines the interaction between an angiopoietin-1 mimetic peptide, QHREDGS (glutamine-histidine-arginine-glutamic acid-aspartic acid-glycine-serine (SEQ ID NO: 1)) immobilized to a collagen-chitosan hydrogel, and murine bone marrow derived macrophages. When macrophages were cultured in the presence of the peptide conjugated to a hydrogel, both pro-inflammatory and anti-inflammatory cytokines were produced, in contrast to the application of soluble peptide which elicited minimal cytokine secretion. This indicates a unique macrophage polarization with covalently immobilized peptide hydrogels, which can be beneficial in the context of the wound microenvironment.
Abstract: Among the various aspects of the present disclosure is the provision of compositions and methods for the treatment of allergic disorders. In some embodiments, the allergic disorder is atopic dermatitis or related allergic disorder thereof. In some embodiments, the method comprises administration of a therapeutically effective amount of an NK cell-stimulating agent, such as an IL-15 superagonist.
Type:
Application
Filed:
October 16, 2020
Publication date:
May 6, 2021
Applicant:
Washington University
Inventors:
Brian Kim, Madison Mack, Jonathan Brestoff Parker